First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
★ Analysts see FY2027 revenue reaching $10.0B — +29.7% growth in a single year.
What Moves the Stock
1New PPP contract wins with state governments - each major tender (e.g., Maharashtra, Karnataka expansions) can add 200-400 centers and ₹500M-1B in annual revenue
2Same-center scan volume growth - utilization rates at existing facilities (currently estimated 40-50% of capacity) drive margin expansion without incremental capex
growth - Company is in rapid expansion phase (15.7% revenue growth, 200+ annual center additions) with negative FCF as it invests for scale.
Rising rates have moderate negative impact through two channels: (1) Higher borrowing costs for capex financing - company has ₹1.3B annual…
Watch on earnings: Indian government healthcare expenditure as % of GDP (currently 2.1%, target 2.5% by 2025) - drives PPP tender pipeline, Ayushman Bharat beneficiary enrollment and claims processed - indicates utilization of government health schemes that fund diagnostic reimbursements, State-level fiscal deficit ratios - states with >3% deficits may delay tender releases or extend payment cycles.
One Sentence Summary:
Krsnaa Diagnostics: the story is balanced — new ppp contract wins with state governments - each major tender (e.g., maharashtra.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.